Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences

Rhea-AI Summary

Acadia Pharmaceuticals (ACAD) announced its participation in three upcoming investor conferences in May 2024, aiming to engage with the investment community. The company will host fireside chats at each conference, providing insights into its innovative work in neuroscience. Acadia has a strong track record with FDA-approved drugs for Parkinson's disease psychosis and Rett syndrome, while also focusing on developing treatments for Prader-Willi syndrome, Alzheimer's disease psychosis, and other neuropsychiatric disorders.

Positive

• Established presence in neuroscience with FDA-approved drugs for Parkinson's disease psychosis and Rett syndrome.

• Active participation in investor conferences to engage with the investment community and showcase breakthroughs in neuroscience.

• Focus on clinical-stage development efforts targeting various neuropsychiatric symptoms in central nervous system disorders, highlighting a commitment to innovation and addressing unmet medical needs.

Negative

• None.

SAN DIEGO--(BUSINESS WIRE)-- Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate at three upcoming investor conferences:

Citizens JMP Life Sciences Conference
Fireside Chat: Tuesday, May 14, 2024 at 1:30 p.m. Eastern Time in New York, NY

2024 RBC Capital Markets Global Healthcare Conference
Fireside Chat: Wednesday, May 15, 2024 at 11:30 a.m. Eastern Time in New York, NY

BofA Securities Health Care Conference
Fireside Chat: Wednesday, May 16, 2024 at 12:20 p.m. Eastern Time in Las Vegas, NV

Live webcasts of each fireside chat will be accessible on the company’s website, Acadia.com, under the investors section and an archived recording will be available on the website for approximately one month following each presentation.

About Acadia Pharmaceuticals

Acadia is advancing breakthroughs in neuroscience to elevate life. For 30 years we have been working at the forefront of healthcare to bring vital solutions to people who need them most. We developed and commercialized the first and only FDA-approved drug to treat hallucinations and delusions associated with Parkinson’s disease psychosis and the first and only FDA-approved drug for the treatment of Rett syndrome. Our clinical-stage development efforts are focused on Prader-Willi syndrome, Alzheimer’s disease psychosis and multiple other programs targeting neuropsychiatric symptoms in central nervous system disorders. For more information, visit us at Acadia.com and follow us on LinkedIn and Twitter.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240507861038/en/

Investor Contact:

Acadia Pharmaceuticals Inc.

Al Kildani

(858) 261-2872

ir@acadia-pharm.com

Acadia Pharmaceuticals Inc.

Jessica Tieszen

(858) 261-2950

ir@acadia-pharm.com

Source: Acadia Pharmaceuticals Inc.

FAQ

When will Acadia Pharmaceuticals participate in the Citizens JMP Life Sciences Conference?

Acadia Pharmaceuticals will participate in the Citizens JMP Life Sciences Conference on Tuesday, May 14, 2024, at 1:30 p.m. Eastern Time in New York, NY.

What are Acadia Pharmaceuticals' focus areas in its clinical-stage development efforts?

Acadia Pharmaceuticals focuses on Prader-Willi syndrome, Alzheimer's disease psychosis, and multiple other programs targeting neuropsychiatric symptoms in central nervous system disorders.

Where can I access live webcasts of Acadia Pharmaceuticals' fireside chats?

Live webcasts of Acadia Pharmaceuticals' fireside chats will be accessible on the company's website, Acadia.com, under the investors section.